TY - JOUR
T1 - Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients
AU - Koiwa, Fumihiko
AU - Komukai, Daisuke
AU - Hirose, Makoto
AU - Yoshimura, Ashio
AU - Ando, Ryoichi
AU - Sakaguchi, Toshifumi
AU - Komatsu, Yasuhiro
AU - Shinoda, Toshio
AU - Inaguma, Daijo
AU - Joki, Nobuhiko
AU - Nishida, Hidemi
AU - Ikeda, Masato
AU - Shigematsu, Takashi
PY - 2012/2
Y1 - 2012/2
N2 - Introduction: The aim of this study was to investigate the factors influencing serum parathyroid (PTH) levels, including medications for treating chronic kidney disease-mineral and bone metabolism disorder (CKD-MBD) in patients with end-stage renal disease. Methods: We enrolled 1,076 patients in nine Japanese facilities who had begun hemodialysis (HD) due to ESRD. We investigated the relationships between intact PTH (iPTH) levels and clinical parameters and medications just prior to beginning HD. Results: Significant decreases in serum iPTH levels were seen in males, in the presence of diabetes mellitus (DM), and with administration of renin-angiotensin system inhibitors (RASIs). Significant correlations were found between serum calcium and iPTH levels. In the patients administered RASIs, there was a significant decrease in serum iPTH levels with DM, male gender, and administration of active vitamin D sterols (VDs) compared with those not administered RASIs, although serum-corrected calcium levels were not different. Multiple regression analysis found gender, age, presence of DM, and serum calcium and phosphate levels to be significant contributing factors. In addition, administration of angiotensin II receptor blockers (ARBs) may also be a contributing factor to iPTH levels at the beginning HD (p = 0.050). Conclusion: In this study, serum iPTH levels were related to administration of ARBs besides gender, age, the presence of DM and serum calcium levels. Our study suggests that the RA system involve serum iPTH levels in uremic patients.
AB - Introduction: The aim of this study was to investigate the factors influencing serum parathyroid (PTH) levels, including medications for treating chronic kidney disease-mineral and bone metabolism disorder (CKD-MBD) in patients with end-stage renal disease. Methods: We enrolled 1,076 patients in nine Japanese facilities who had begun hemodialysis (HD) due to ESRD. We investigated the relationships between intact PTH (iPTH) levels and clinical parameters and medications just prior to beginning HD. Results: Significant decreases in serum iPTH levels were seen in males, in the presence of diabetes mellitus (DM), and with administration of renin-angiotensin system inhibitors (RASIs). Significant correlations were found between serum calcium and iPTH levels. In the patients administered RASIs, there was a significant decrease in serum iPTH levels with DM, male gender, and administration of active vitamin D sterols (VDs) compared with those not administered RASIs, although serum-corrected calcium levels were not different. Multiple regression analysis found gender, age, presence of DM, and serum calcium and phosphate levels to be significant contributing factors. In addition, administration of angiotensin II receptor blockers (ARBs) may also be a contributing factor to iPTH levels at the beginning HD (p = 0.050). Conclusion: In this study, serum iPTH levels were related to administration of ARBs besides gender, age, the presence of DM and serum calcium levels. Our study suggests that the RA system involve serum iPTH levels in uremic patients.
UR - http://www.scopus.com/inward/record.url?scp=84858276072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858276072&partnerID=8YFLogxK
U2 - 10.1007/s10157-011-0534-x
DO - 10.1007/s10157-011-0534-x
M3 - Article
C2 - 21912899
AN - SCOPUS:84858276072
SN - 1342-1751
VL - 16
SP - 130
EP - 135
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 1
ER -
